Biogen (BIIB) Income from Continuing Operations (2009 - 2026)
Biogen (BIIB) posted quarterly Income from Continuing Operations of 97500000.0 for Q2 2026, down 84.64% year-over-year from 634800000.0 in Q2 2025, and down 69.48% quarter-over-quarter from 319500000.0 in Q1 2026.
Biogen (BIIB) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Biogen's Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 97500000.0 for Q2 2026.
- In Q2 2026, Income from Continuing Operations fell 84.64% year-over-year to 97500000.0; the TTM figure through Jun 2026 stood at 834600000.0 (down 45.47% YoY), while the FY2025 annual figure was 1292900000.0, down 20.79% from the prior year.
- Income from Continuing Operations for Q2 2026 stood at 97500000.0, down from 319500000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1134900000.0 in Q3 2022, with the low at 68300000.0 in Q3 2023.
- The 5-year median for Income from Continuing Operations is 388050000.0 (2023), against an average of 414588888.89.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations jumped 1538.48% in 2022, then slumped 118.34% in 2025.
- Biogen's Income from Continuing Operations stood at 549500000.0 in 2022, then slumped by 54.7% to 248900000.0 in 2023, then gained by 7.15% to 266700000.0 in 2024, then plunged by 118.34% to 48900000.0 in 2025, then surged by 299.39% to 97500000.0 in 2026.
- Business Quant data shows BIIB's Income from Continuing Operations at 97500000.0 in Q2 2026, 319500000.0 in Q1 2026, and 48900000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 97.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.50 Mn |
| Mar 31, 2026 | 319.50 Mn |
| Dec 31, 2025 | -48.90 Mn |
| Sep 30, 2025 | 466.50 Mn |
| Jun 30, 2025 | 634.80 Mn |
| Mar 31, 2025 | 240.50 Mn |
| Dec 31, 2024 | 266.70 Mn |
| Sep 30, 2024 | 388.50 Mn |
| Jun 30, 2024 | 583.60 Mn |
| Mar 31, 2024 | 393.40 Mn |
| Dec 31, 2023 | 248.90 Mn |
| Sep 30, 2023 | -68.30 Mn |
| Jun 30, 2023 | 593.30 Mn |
| Mar 31, 2023 | 387.60 Mn |
| Dec 31, 2022 | 549.50 Mn |
| Sep 30, 2022 | 1.13 Bn |
| Jun 30, 2022 | 1.05 Bn |
| Mar 31, 2022 | 221.80 Mn |
| Dec 31, 2021 | -38.20 Mn |
| Sep 30, 2021 | 317.00 Mn |